The role of gliflozins in unconventional ways of improving cardiometabolic control as a cardioprotective strategy in women with type 2 diabetes mellitus and heart failure with preserved ejection fraction
Clinical Endocrinology and Endocrine Surgery · 30.06.2026 · (2) · 41-51
DOI: 10.30978/cees-2026-2-41 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology and Endocrine Surgery, online erschienen am 30.06.2026. Verfasst von L. R. Petrovska und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Themen: Diabetes mellitus, Herzinsuffizienz
Abstract (Originalsprache)
Sodium–glucose cotransporter-2 inhibitors (SGLT2i, gliflozins), beyond their glucose-lowering effects, exert pleiotropic metabolic actions, including attenuation of systemic inflammation, modulation of the adipocytokine profile associated with visceral obesity, and direct cardioprotective effects mediated by energetic, structural, and microvascular mechanisms. These mechanisms provide a pathophysiological rationale for the expanding use of SGLT2i as a cardiometabolic therapeutic strategy, particularly in women with type 2 diabetes mellitus (T2DМ) and heart failure with preserved ejection fraction (HFpEF). Objective — to evaluate the non-conventional mechanisms and clinical efficacy of the cardioprotective effects of gliflozins in women with T2DM and HFpEF. Materials and methods. This prospective cohort study included 64 women with T2DM and HFpEF. According to glucose-lowering therapy, participants were assigned to three groups: group 1 (n=16) received metformin (MET, 2000 mg/day) plus dapagliflozin (DAPA, 10 mg/day); group 2 (n=16) received MET (2000 mg/day) in combination with empagliflozin (EMPA, 10 — 25 mg/day); group 3 (n=32) received MET monotherapy (2000 mg/day). Anthropometric, biochemical, and clinical-instrumental parameters were assessed at baseline and after 12 weeks of treatment. Results. Twelve-week treatment with gliflozins (DAPA, EMPA) in combination with MET in women with T2DM and HFpEF resulted in a multilevel cardiometabolic effect. Compared with MET monotherapy, combined MET and SGLT2i therapy resulted in improved glycaemic control, with a reduction in HbA1c in Gr 1 (β=−0.49; p=0.005) and Gr 2 (β=−0.47; p=0.008), as well as fasting capillary blood glucose (β=−0.95 and β=−0.64, respectively; both p
Zitieren
APA
Petrovska, L. R., Kostitska, I. O., Petrovskyy, T. R., & Petrovskyy, R. V. (2026). The role of gliflozins in unconventional ways of improving cardiometabolic control as a cardioprotective strategy in women with type 2 diabetes mellitus and heart failure with preserved ejection fraction. Clinical Endocrinology and Endocrine Surgery, 41-51. https://doi.org/10.30978/cees-2026-2-41
Vancouver
Petrovska LR, Kostitska IO, Petrovskyy TR, Petrovskyy RV. The role of gliflozins in unconventional ways of improving cardiometabolic control as a cardioprotective strategy in women with type 2 diabetes mellitus and heart failure with preserved ejection fraction. Clinical Endocrinology and Endocrine Surgery. 2026:41-51. doi:10.30978/cees-2026-2-41
BibTeX
@article{Petrovska2026,
author = {Petrovska, L. R. and Kostitska, I. O. and Petrovskyy, T. R. and Petrovskyy, R. V.},
title = {The role of gliflozins in unconventional ways of improving cardiometabolic control as a cardioprotective strategy in women with type 2 diabetes mellitus and heart failure with preserved ejection fraction},
journal = {Clinical Endocrinology and Endocrine Surgery},
year = {2026},
number = {2},
pages = {41--51},
doi = {10.30978/cees-2026-2-41}
}
EUVIMED